Revenue
2022
2023
2024
2025
Sionna Therapeutics, Inc. (SION)
Price$7.18Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research & development | $60.3M | $57.3M | $40.6M | $34.6M |
| Operating expenses | $89.0M | $70.6M | $50.3M | $41.4M |
| Operating income | −$89.0M | −$70.6M | −$50.3M | −$41.4M |
| EBITDA | −$88.3M | −$69.9M | −$49.8M | −$41.3M |
| Net income | −$75.3M | −$61.7M | −$47.3M | −$40.2M |
| Basic EPSper basic share | -$1.88 | -$15.99 | -$1.70 | -$2.32 |
| Diluted EPSper diluted share | -$1.88 | -$15.99 | -$1.70 | -$2.32 |
Owners
Reported shareholders
21.93%of listed shares
RA CAPITAL MANAGEMENT, L.P.9.91M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | 21.93%9.91M shares |
TPG GP A, LLC | 14.38%6.49M shares |
Atlas Venture Fund XI, L.P. / Atlas Venture Associates XI, LLC / Atlas Venture Associates Opportunity II, LP / Atlas Venture Associates Opportunity II, LLC / Atlas Venture Opportunity Fund II, L.P. / Atlas Venture Associates XI, L.P. | ≈9.83%4.44M shares |
VIKING GLOBAL INVESTORS LP | 7.07%3.2M shares |
Booth Bruce | ≈6.63%3M shares |
Atlas Venture Life Science Advisors, LLC | 6.63%3M shares |
Thompson Peter A. | ≈5.92%2.67M shares |
ORBIMED ADVISORS LLC | 5.66%2.56M shares |
ENAVATE SCIENCES GP, LLC | 5.49%2.48M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.54%1.6M shares |
JPMORGAN CHASE & CO | 3.30%1.49M shares |
BlackRock, Inc. | 3.27%1.47M shares |
JENNISON ASSOCIATES LLC | 2.60%1.17M shares |
CITADEL ADVISORS LLC | 2.54%1.15M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.51%1.13M shares |
STATE STREET CORP | 2.26%1.02M shares |
PERCEPTIVE ADVISORS LLC | 2.00%905K shares |
DEERFIELD MANAGEMENT COMPANY, L.P. | 1.51%680.92K shares |
Siren, L.L.C. | 1.35%610.52K shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 1.06%478.02K shares |
Percentages use 45.16M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 27, 2026Form 4 · 10b5-1 | Thompson Peter A.Director | SellCommon Stock · indirect | 101 | $44.49 | $4.5K | 2.67M |
| May 27, 2026Form 4 · 10b5-1 | ORBIMED ADVISORS LLC +1Director | SellCommon Stock · indirect | 101 | $44.49 | $4.5K | 2.67M |
| May 11, 2026Form 4 · 10b5-1 | Thompson Peter A.Director | SellCommon Stock · indirect | 184.6K | $46.22 | $8.53M | 2.67M |
| May 11, 2026Form 4 · 10b5-1 | ORBIMED ADVISORS LLC +1Director | SellCommon Stock · indirect | 184.6K | $46.22 | $8.53M | 2.67M |
| May 8, 2026Form 4 · 10b5-1 | Thompson Peter A.Director | SellCommon Stock · indirect | 59.8K | $44.58 | $2.66M | 2.86M |